Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-2: KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma
2015-005008-27Phase 2Active
- Sponsor
- Kite Pharma
- Start
- May 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Kite Pharma. Primary endpoint: Objective response rate. Started May 2016; status: active.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2015-005008-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005008-27.